with a favorable prognosis in several cancer types. [12] [13] [14] [15] The HDAC family consists of 18 members, which are classified into 4 major classes: Class I (HDAC 1,2,3,8), Class II (HDAC 4,5,6,7,9,10), Class III (Sirt1 to Sirt7) and Class IV (HDAC11). 16 HDAC inhibitors represent the first success of epigenetic-based cancer therapy. 17 
Among them, vorinostat (suberoylanilide hydroxamic acid [SAHA])
inhibits HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8 through coordination with the catalytic Zn(II) structure and has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of the cutaneous manifestations of cutaneous T-cell lymphoma. [18] [19] [20] [21] BRD4 is the most thoroughly studied member of the BET family proteins, which consists of 4 members in humans, BRD2, BRD3, BRD4 and the bromodomain testis-specific protein (BRDT). 10 BRD4
recognizes the acetylated lysine on the nucleosomal histones via its tandem N-terminal bromodomains and functions as a transcription regulator via its C-terminal bromodomains, through which BRD4 interacts and recruits positive transcription elongation factor b (pTEFb), a heterodimer composed of cyclin-dependent kinase 9
(CDK9) and its regulator cyclin T, which phosphorylates serine 2 on the C-terminal bromodomain of RNA pol II for mRNA transcript elongation. [22] [23] [24] [25] [26] [27] BRD4 has been shown to couple histone acetylation to transcript elongation and increase the transcription of various important genes such as MYC and BCL2. [28] [29] [30] [31] [32] Therefore, BRD4
is involved in modulation of a wide range of biological functions that are potentially relevant to the treatment of cancers, including apoptosis, cell cycle, growth, proliferation, differentiation and invasion. 21 As a result, BET bromodomains are promising therapeutic targets for cancers, and several BET inhibitors, for example JQ1, have been developed in recent ten years that competitively bind to acetyl-lysine recognition pockets and displace BET proteins from chromatin. 21, 33 Both BRD4 and HDAC are related to epigenetic regulation of gene expression via histone acetylation, and their inhibitors have similar genes and biological effects in cancers. 34 Combinations of HDAC inhibitors with BET inhibitors have become a research hotspot and have shown efficacy in several cancer types. 10, 32, 35, 36 However, little is yet known about the effects or mechanisms of either HDAC inhibitors or BET inhibitors, let alone their cotreatment on human GBC cells.
In this study, we explored the anticancer effects of JQ1, SAHA
and their combination on GBC cells and investigated the underlying mechanisms mediating these effects. We found that both JQ1 and SAHA suppressed cell viability, proliferation, metastasis and invasion, and induced apoptosis and cell cycle arrest in vitro. Meanwhile, JQ1 and/or SAHA treatments dramatically inhibited the growth of GBC in vivo. These effects were accompanied with a significant downregulation of BRD4 expression and suppression of PI3K/AKT and MAPK/ERK signaling pathways. More importantly, we found that cotreatment with JQ1 and SAHA is more effective than treatment with a single agent alone both in vitro and in vivo, suggesting that combination treatment with JQ1 and SAHA might be a promising new strategy for the treatment of GBC. 
| MATERIAL S AND ME THODS

| Reagents
| Cell culture
The human GBC cell lines (NOZ, SGC-996 and GBC-SD) and benign cells 293T were obtained from the Cell Bank of the Type Culture
Collection of the Chinese Academy of Sciences (Shanghai, China).
All experiments with cell lines were performed within 6 months after thawing or cells being obtained. NOZ cells were cultured in
Williams' medium and SGC-996 were cultured in RPMI-1640 medium (Hyclone). The GBC-SD and 293T cells were cultured in DMEM (Gibco). All cells were supplemented with 100 μg/mL streptomycin, 100 U/mL penicillin (Hyclone) and 10% FBS (Gibco), and maintained at 37°C in a 5% CO 2 humidified incubator.
| Cell viability assay, calculation of GI 50 and combination index
The viability of cells treated with drugs was measured by CCK-8 assay.
Cells were seeded into 96-well plates at a density of 3000 cells/well, cultured for 16-24 hours and subsequently treated with defined concentration ranges of JQ1 or SAHA for 48 hours to determine the GI 50 .
And then the cells were treated with various concentrations of JQ1
or SAHA based on their GI 50 in each cell line for 24, 48 or 72 hours.
CCK-8 (10 μL) was added to each well after treatment and the cells were incubated for exactly 120 minutes away from light. The absorbance value (OD) was measured at 450 nm using a microplate reader (Bio-Tek). Cell viability was calculated as follows: cell viability = (OD of control − OD of treatment)/(OD of control − OD of blank) × 100%.
The assay in each cell line was repeated 3 times. For determination of drug synergy, different combinations of dose of JQ1 and SAHA were chosen based on the 48 hour GI 50 of each cell line and combination index (CI) scores were calculated using the Chou-Talalay method and
CompuSyn software. 37 For this analysis, we entered the combination treatment data, along with the data obtained from single agent treatments, into CompuSyn to determine the CI value for each combination point. The CI value quantitatively defines antagonism (CI > 1.5), additivity (1 < CI < 1.5) and synergy (CI < 1), and the results are shown as the classic isobologram. The cell line-dependent GI 50 and 48 hour combination concentrations used for subsequent analyses are given in Table 1 . As for the determination of the drug synergy using cell line-dependent GI 50 , the value (q) was determined by the fractional product equation of Webb. 37 In this part, the q value quantitatively defines antagonism (q < 1.0), additivity (q = 1.0) and synergy (q > 1.0), and the results are shown as a column chart.
| Colony-forming assay
The cells were seeded into 6-well plates at a density of 500 cells/ well 48 hours post-drug treatment for 7-10 days. Then the colonies were fixed with 4% paraformaldehyde for 30 minutes and stained with 0.1% crystal violet (Sigma-Aldrich) for 20 minutes. The colonies were observed under a microscope (Leica) and photographed after washing and drying up the plates.
| Migration and invasion assay
Twenty-four-well Transwell chamber inserts (Corning, Corning, Then 400 μL of the binding buffer was added to the suspension.
The samples were then immediately measured by flow cytometry (FACSCalibur BD). 
| Cell cycle analyses
| Western blot analysis
Protein was extracted by lysis for 30 minutes on ice in RIPA buffer 
| Quantitative real-time PCR
Total RNA was extracted from cells using TRIzol Reagent. cDNA was forward: 5′-ACAACAAGCCTGGAGATGACA-3′, BRD4 reverse:
5′-GTTTGGTACCGTGGAAACGC-3′.
| siRNA and plasmid transfection
BRD4 siRNA (5′-CCUGAUUACUAUAAGAUCAdTdT-3′) was designed and synthesized by Biotend. BRD4-siRNA or NC-siRNA was 
| In vivo nude mouse subcutaneous xenograft model
All in vivo studies were approved by the Ethics Committee of 
| Immunohistochemistry
Tumors were stored in 4% paraformaldehyde were then embedded in paraffin, cut into 5-mm sections and mounted on slides. The expression of BRD4, Ki-67, PCNA, cleaved caspase-3, p-AKT and p-ERK1/2 were analyzed by immunohistochemical streptavidinperoxidase staining (IHC). Pictures were taken using a microscope (Leica) and the analysis of IHC was done using ImageJ software by measuring pixel units.
| Statistical analysis
All assays were performed at least 3 times. Statistical analysis was per- 293T (Figure 2A,B) . Meanwhile, strong synergies (CI < 1) were detected in GBC cell lines based on cell viability results using the ChouTalalay method. 37 In contrast, only mild synergy of the combination treatment was seen in 293T ( Figure 2C ). Dosages for the combined treatment were listed in the Table 1 . Then, a colony formation assay was performed to determine the proliferation capacity of single cells.
The co-treatment synergistically suppressed long-term proliferation more than each inhibitor alone at the same doses in all GBC cell lines ( Figure 2D ). To further confirm that the synergistic effects by the combination of JQ1 and SAHA were mediated by HDAC inhibition, but not other off-target effects. We repeated the colony formation assay using another HDAC inhibitor entinostat (MS-275; the treatment dose of MS-275 was 2.5 μmol/L (lower than its GI 50 in each cell line). The results of MS-275 were similar to those for SAHA, which proved that HDAC inhibition was involved in the synergistic effects of JQ1 and SAHA ( Figure 2E ).
| Combination treatment with JQ1 and suberoylanilide hydroxamic acid synergistically inhibits the metastasis of gallbladder cancer cells
A Transwell assay was performed in GBC cell lines to evaluate the effect of JQ1 and SAHA in mediating cell migration and invasion.
The results indicated that treatment with either JQ1 or SAHA alone significantly weakened the migration and invasion capacities of GBC cells and their cotreatment, resulting in synergies ( Figure 3A-E) .
Furthermore, the expression of epithelial-mesenchymal transition (EMT)-related proteins was analyzed by western blot. The results
showed that the treatment increased the expression of ZO-1 and E-cadherin while inhibiting the expression of N-cadherin, vimentin, MMP-2 and MMP-9, suggesting that JQ1 and SAHA inhibited and had synergistic effect in the EMT process of GBC ( Figure 3F ).
| JQ1 and suberoylanilide hydroxamic acid synergistically induce apoptosis in gallbladder cancer cells
To explore whether cell apoptosis is implicated in anticancer effects Bcl-2, in particular, the ratio of Bcl-2/Bax. In addition, the cotreatment showed a stronger effect than single treatment ( Figure 4D ,E).
| JQ1 and suberoylanilide hydroxamic acid synergistically induce G2/M phase cell cycle arrest in gallbladder cancer cells
To characterize the cellular effects of JQ1, SAHA and their combina- 
| JQ1 and suberoylanilide hydroxamic acid synergistically inhibit tumor growth in vivo
We next determined the in vivo anticancer activity of JQ1 and/ or SAHA against the NOZ tumor xenografts in the nude mice.
The anticancer effects due to treatment with intraperitoneal JQ1
and/or SAHA for 4 weeks were compared with the effects of the treatment with vehicle alone. We found that treatment with either JQ1 or SAHA significantly inhibited the growth of tumor F I G U R E 5 JQ1 and suberoylanilide hydroxamic acid (SAHA) exerted anticancer effects through downregulation of BRD4 and suppression of PI3K/AKT and MAPK/ERK pathways. A, The BRD4 mRNA expression was determined by quantitative RT-PCR. B, BRD4, histone deacetylases (HDAC), histone acetylation and autophagy level were detected by western blot. C, Expression levels of BRD4 and HDAC after pretreatment with bortezomib and then JQ1 and/or SAHA. D, Expression levels of PI3K/AKT and MAPK/ERK pathway proteins were determined by western blot. Significant differences are indicated by *P < 0.05, **P < 0.01 and ***P < 0.001 volume and weight, and co-treatment with JQ1 and SAHA to- 
| D ISCUSS I ON
In this study, we demonstrated for the first time that BET inhibitor In recent years, the anticancer activity of BET inhibitors and/ or HDAC inhibitors has been proved effective in various cancer types, 10, 32, 36, [40] [41] [42] but their effects on GBC have remained largely unknown. In this study, it was found that either JQ1 or SAHA alone
can significantly inhibit GBC cell viability and proliferation in GBC cells, and their combination is associated with synergistic effects; meanwhile, these effects on 293T cells were much weaker. Thus, we can assume that JQ1 and SAHA are effective and safe agents, and their combination is a promising strategy for the treatment of GBC.
Gallbladder cancer is characterized by high rates of recurrence, early lymph node invasion and metastasis to distant organs, due to which most deaths of patients occur. 43 EMT plays a critical role in tumor invasion, metastasis and therapeutic resistance. Thus, inhibiting the EMT process is vital for improving the survival rate of GBC patients. In this study, we conducted migration and invasion assays which showed that JQ1 and SAHA remarkably decreased the migration and invasion ability and exerted synergistic effects in GBC cells. Tumors were weighed. q value > 1.0 indicates synergy. E, Proteins were extracted from the tumors and BRD4, cyclin B1, cleaved caspase-3, p-AKT and p-ERK1/2 expression levels were analyzed by western blot. All data are presented as mean ± SD. q value is shown as a column chart and: <1.0 indicates antagonism, =1.0 additivity, >1.0 synergy. Significant differences are indicated by *P < 0.05, **P < 0.01, and ***P < 0.001 vs negative control (NC); a: P < 0.05 JQ1 vs JQ1 + SAHA; b: P < 0.05, SAHA vs JQ1 + SAHA Appropriate apoptotic signaling is fundamentally important to preserve a healthy balance between cell death and cell survival and for maintaining genome integrity. 44 In this study, we found that JQ1 and/or SAHA-induced apoptosis can occur via both the intrinsic and extrinsic pathways. Caspase-3 is a key executioner that can subsequently cleave numerous important cellular substrates such as PARP, and, ultimately, lead to apoptosis. In this study, we found that JQ1 and/or SAHA significantly increased the expression of cleaved caspase-3 both in vitro and in vivo. In addition, a significant increase in the expression of Bad and a decrease in the ratio of Bcl-2/Bax, accompanied with a dramatic increase in cytochrome c, cleaved caspase-9, caspase-7 and PARP, were also observed, suggesting that intrinsic apoptosis was involved in the apoptosis induced by JQ1 and/or SAHA.
Moreover, cleavage of caspase-8 was also found to be significantly upregulated after treatment with JQ1 and/or SAHA, which is associated with the initiation of the extrinsic apoptosis pathway. 45 In addition, other important apoptosis-related proteins, such as c-MYC, NF-κB, p53 and p-p53, were also found altered in this study, supporting the pro-apoptotic effects of JQ1 and SAHA. More importantly, combination of JQ1 and SAHA exerted the strongest pro-apoptotic effects.
The above results further provide evidence that co-treatment with JQ1 and SAHA can be a valid strategy for the treatment of GBC.
Successful progression through the cell cycle is controlled by a number of different regulatory mechanisms termed checkpoints. 46 The checkpoints are frequently observed defective and nonfunctional in many cancer types and, therefore, could be exploited to F I G U R E 8 Immunohistochemistry results. BRD4, Ki-67, PCNA, cleaved caspase-3, p-AKT and p-ERK1/2 expression levels were analyzed using IHC staining. Bar charts showed the relative expression of the above indicators. All data are presented as mean ± SD. Significant differences are indicated by *P < 0.05, **P < 0.01 and ***P < 0.001 vs negative control (NC); a: P < 0.05 JQ1 vs JQ1 + SAHA; b: P < 0.05, SAHA vs JQ1 +SAHA target tumor cells by anticancer treatment and result in cell cycle arrest at a specific checkpoint. 46, 47 We performed flow cytometry to investigate the cell cycle distribution. The results showed that JQ1
and SAHA synergistically increased the proportion of G2/M cells. In addition, the major players that regulate induction and maintenance of the G2 checkpoint, such as p53, p27 Kip1, CDK1, CDK2 and cyclin B1, were found significantly altered by western blot. 46 
D I SCLOS U R E
The authors declare no conflicts of interest for this article.
O RCI D
Shilei Liu
https://orcid.org/0000-0003-1700-4385
Lijia Pan https://orcid.org/0000-0001-5977-9555
Ziyi Yang https://orcid.org/0000-0001-5883-9552
R E FE R E N C E S
